# Tenecteplase

Drug · id `cardio:tenecteplase` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: TNKase; TNK-tPA

Browse, organ or system: Heart; Brain  
Browse, condition area: Coronary and vascular disease; Stroke  

## In plain language

Tenecteplase, sold as TNKase, is a clot-dissolving medicine, a tissue plasminogen activator, given into a vein. The US label read lists two uses, both in adults: the treatment of acute ischemic stroke, and reducing the risk of death associated with acute ST-elevation myocardial infarction (STEMI). The label says it binds to fibrin and converts plasminogen to plasmin.

## Technical summary

RxNorm ingredient 259280; MeSH descriptor D000077785 is Tenecteplase. It is a biologic: the openFDA record carries no UNII, and RxClass returned no FDA class for it, so the class rests on the label's own words (it calls tenecteplase a tissue plasminogen activator and refers to related thrombolytic agents), and MeSH lists Fibrinolytic Agents (D005343) among its pharmacological actions. The label read is the Genentech, Inc. label for TNKase, application BLA103909, effective 2025-12-15 in openFDA. This page records label indications and the class only: no trial result and no dose is given. This is a regulatory record, not a finding about how well the medicine works.

## Claims, with the population each applies to

## Context: Adults for whom the US label of tenecteplase (TNKase) lists an indication: acute ischemic stroke, acute ST-elevation myocardial infarction

Recipient: Adult; Population: Adult patients described in the indications sections of the label.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the passages read state; Follow-up: Not applicable (label statement)

### The US label of TNKase (tenecteplase), in the Genentech, Inc. version dated 2025-12-15 in openFDA, describes the medicine as a tissue plasminogen activator (tPA) and lists it, in adults, for the treatment of acute ischemic stroke (AIS) and to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI).

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adult patients described in the indications sections of the label.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the passages read state; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label has no boxed warning section in openFDA; time limits, contraindications, doses, interactions and bleeding warnings were not read. openFDA also lists a second TNKase record with only the myocardial infarction indication. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for TNKase (tenecteplase), Genentech, Inc. label: indications and mechanism (Regulator, edition The openFDA drug label record for set id e647640d-c395-4b4b-a0be-1162f9c21d84 (manufacturer Genentech, Inc., application BLA103909), returned on 2026-11-09. The label text is dated 2025-12-15 (effective\_time). A second openFDA TNKase record (set id 739a3c53-caf6-40d6-a6af-84ce733a948b, also dated 2025-12-15) lists only the ST-elevation myocardial infarction indication; it was fetched first, replaced by this record because this one lists both indications, and its bytes were never cited.) <https://api.fda.gov/drug/label.json?search=set_id:%22e647640d-c395-4b4b-a0be-1162f9c21d84%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:03Z. Source state: Current. Version fingerprint: 5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for TNKase (tenecteplase), Genentech, Inc. label: indications and mechanism (Regulator, edition The openFDA drug label record for set id e647640d-c395-4b4b-a0be-1162f9c21d84 (manufacturer Genentech, Inc., application BLA103909), returned on 2026-11-09. The label text is dated 2025-12-15 (effective\_time). A second openFDA TNKase record (set id 739a3c53-caf6-40d6-a6af-84ce733a948b, also dated 2025-12-15) lists only the ST-elevation myocardial infarction indication; it was fetched first, replaced by this record because this one lists both indications, and its bytes were never cited.) <https://api.fda.gov/drug/label.json?search=set_id:%22e647640d-c395-4b4b-a0be-1162f9c21d84%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Acute Ischemic Stroke. Retrieved 2026-11-09T13:17:03Z. Source state: Current. Version fingerprint: 5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09.
     How it applies: Label passage quoted in the research quote table (LB-05).
  3. Supports: openFDA drug label record for TNKase (tenecteplase), Genentech, Inc. label: indications and mechanism (Regulator, edition The openFDA drug label record for set id e647640d-c395-4b4b-a0be-1162f9c21d84 (manufacturer Genentech, Inc., application BLA103909), returned on 2026-11-09. The label text is dated 2025-12-15 (effective\_time). A second openFDA TNKase record (set id 739a3c53-caf6-40d6-a6af-84ce733a948b, also dated 2025-12-15) lists only the ST-elevation myocardial infarction indication; it was fetched first, replaced by this record because this one lists both indications, and its bytes were never cited.) <https://api.fda.gov/drug/label.json?search=set_id:%22e647640d-c395-4b4b-a0be-1162f9c21d84%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.2 Acute ST Elevation Myocardial Infarction. Retrieved 2026-11-09T13:17:03Z. Source state: Current. Version fingerprint: 5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09.
     How it applies: Label passage quoted in the research quote table (LB-06).
  4. Background: openFDA drug label record for TNKase (tenecteplase), Genentech, Inc. label: indications and mechanism (Regulator, edition The openFDA drug label record for set id e647640d-c395-4b4b-a0be-1162f9c21d84 (manufacturer Genentech, Inc., application BLA103909), returned on 2026-11-09. The label text is dated 2025-12-15 (effective\_time). A second openFDA TNKase record (set id 739a3c53-caf6-40d6-a6af-84ce733a948b, also dated 2025-12-15) lists only the ST-elevation myocardial infarction indication; it was fetched first, replaced by this record because this one lists both indications, and its bytes were never cited.) <https://api.fda.gov/drug/label.json?search=set_id:%22e647640d-c395-4b4b-a0be-1162f9c21d84%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:03Z. Source state: Current. Version fingerprint: 5e913aaff2ba6e28550a73f2122bc8054e66c3b05b3d92a2f9ca50b37a27ca09.
     How it applies: Effective date of the label text read, 20251215.

## Connected pages

- The label calls tenecteplase a tissue plasminogen activator and names other thrombolytic agents as related to it: Fibrinolytic (clot-dissolving) drugs (`cardio:fibrinolytic-clot-dissolving-drugs`)
- FDA label lists treatment of acute ischemic stroke in adults as an indication: Ischemic stroke (`cardio:ischemic-stroke`) [a claim, not a settled fact; see claim `cardio:claim-fda-tenecteplase-label-indications` and its context]
- FDA label lists reducing the risk of death associated with acute ST elevation myocardial infarction in adults as an indication: ST-elevation heart attack (STEMI) (`cardio:stemi`) [a claim, not a settled fact; see claim `cardio:claim-fda-tenecteplase-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 1 registry product
- 51 registry trials

## Provenance

Content hash: f3cea7d45e4c539a8b89bfed9214be34c8d55a1d72b93a649ed526bc94fc6f6a
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
